Montpellier, September 27th 2010 - Nova Decision and Azasynth announced today a definitive merger agreement to create OriBase Pharma. The new company will offer the pharmaceutical and biotech industries’ most complete set of drug discovery products and services for R&D processes with a commitment to bring to its clients chemically feasible and in vivo active and patentable leads in 24 months.
Both companies were founded in 2007 and worked in close partnership towards the objective of providing their clients with innovative solutions in rational design and chemistry synthesis of drug like molecules. Nova Decision is a in silico drug design based company having a strong expertise in medicinal chemistry applied to of the field of selective protein kinase inhibitors and other pharmaceutically validated targets, while Azasynth is a chemistry company specialized in the development of innovative chemistry processes.
"As an international and innovative contract research organization, this is a decisive move that accelerates our strategy and positions us to win by offering even greater value to our customers and partners. In addition to the clear strategic benefits of combining two highly complementary organizations and product families, we can create substantial shareowner value through significant cost structure improvements and access new growth opportunities", said Aziz Yasri, founder of Nova Decision and CEO at OriBase Pharma. “From our joint technologies, we are able to provide our clients with a unique technology platform, HitFast Discovery®, which is an intelligent combination of in silico drug design and proprietary chemistry processes for efficient medicinal chemistry”, said Louis Delon, co-founder of Azasynth and Business Development Director at OriBase Pharma.
OriBase Pharma’s central office is located at:
Rond Point Benjamin Franklin CS39521
+33 (0) 467 130 102
About Nova Decision
Our mission is to provide medicinal chemistry-based lead discovery products & services to pharmaceutical, biotechs and agrochemical companies in drug discovery and crop protection areas. As a computational chemistry company, Nova Decision is involved in all drug discovery stages from Hit Identification to Lead Optimization to the delivery of new drug candidates quickly and at lower cost than competitors. Nova Decision has worked on a wide range of therapeutic target classes and has a specific expertise in kinase inhibitors design. Using its innovative approach and its proprietary technology platform, the company successfully designs and develops new product candidates for cancer and autoimmune diseases among others.
Azasynth is a company specialized in the synthesis of innovative heterocyclic building blocks and final product libraries. Our products are intended for research laboratories in pharmaceuticals, biotechs and agrochemicals industries. Using our expertise in the field of heterocyclic chemistry, we derive novel products from a variety of cores such as pyrroles, azaindoles, quinolines or azaindolizines. Many compounds available in our catalogue are supplied exclusively by our company. www.azasynth.com